avenuetx.com (ATXI) - Long-Term Liabilities to Capital
Avenue Therapeutics (ATXI) operates in a non-cyclical sector where demand for brain disorder treatments remains stable regardless of economic conditions. This price action chart on GURU.Markets reflects the 0.00 metric. Market capitalization is based on the development of emergency care tools and government contracts, while the continuity of testing is guaranteed by a streamlined component delivery system and a network of external laboratories.
&width=1200&height=400&colorIndex=0&v=mvx9zauv.4e-7b561vk&start=20220704&end=20261101&filename=GURU_Markets_-_ATXI_-_Avenue-Therapeutics_-_Long-Term-Debt-to-Equity-Ratio "ATXI - Avenue Therapeutics, Inc. Long-Term Debt to Capital over the range 07/04/2022 - 03/29/2025 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for Avenue Therapeutics (ATXI)
- current price and projected stock value:
- market capitalization indicators:
- book value of equity indicators:
- debt obligations and liquidity statistics:
Debt to Capital Avenue Therapeutics|ATXI - Long-Term Debt to Capital|Short-Term Debt to Capital avenuetx.com|ATXI - Company Total Debt|Debt to Book Capitalization Ratio Avenue Therapeutics, Inc.|ATXI - Company Long-Term Debts|Short-Term Debt Avenue Therapeutics|Immediate Liquidity Ratio avenuetx.com
- net income and valuation ratios data:
General company analysis:Avenue Therapeutics Inc.
This metric measures the proportion of long-term liabilities relative to equity, determining the company's level of financial leverage. For Avenue Therapeutics (ATXI), with its limited resources, this balance is critical when interacting with the FDA. Analysis of the long-term debt-to-equity chart allows for the identification of hidden risks associated with debt financing. Rising leverage may signal a liquidity shortage. Investors should evaluate this trend as an indicator of business sustainability.
Key competitors
Long-Term Debt to Capital Ratio BIIB (Biogen Inc)|Long-Term Debt to Capital NBIX|RGC - Long-Term Liabilities to Capital|Axsome Therapeutics - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital acadia-pharm.com ACAD|XENE - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient VKTX (Viking Therapeutics Inc)|Supernus Pharma (SUPN) - Long-Term Debt to Equity|Long-Term Liabilities to Capital Catalyst Corp (CPRX)|DNLI (Denali Therapeutics) - Long-Term Debt to Capital|Long-Term Debt to Capital harmonybiosciences.com|Long-Term Debt to Equity Ratio BHVN (Biohaven)|Long-Term Debt to Equity AMLX (Amylyx Pharmaceuticals Inc)|Long-Term Debt to Capital TRVI (Trevi Pharma)|Praxis Corp (PRAX) - Long-Term Liabilities to Capital|AVXL - Long-Term Debt to Equity|CBLL (ceribell.com) - Long-Term Debt to Capital Ratio|PRTA (Prothena Corp) - Long-Term Debt to Equity Ratio|Alector (ALEC) - Long-Term Debt to Capital|ANNX (Annexon Inc.) - Long-Term Debt to Capital|Long-Term Liabilities to Capital Omeros Corp. OMER|Long-Term Debt to Equity Ratio NGNE (Neurogene Inc.)|ACIU (acimmune.com) - Long-Term Debt to Capital Coefficient|Voyager Therapeutics, Inc. - Long-Term Debt to Equity Ratio|Long-Term Loans to Capital Ratio NMRA (Neumora)|Scilex Holding Co. - Long-Term Debt to Capital|Long-Term Debt to Capital Coefficient TVGN (Tevogen Bio Inc.)|ACOG: Long-Term Debt to Capital|Long-Term Liabilities to Capital cogrx.com (CGTX)|Long-Term Debt to Equity Inhibikase Therapeutics, Inc.|SAVA: Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ASRT|Long-Term Debt to Capital coyatherapeutics.com (COYA)|Long-Term Debt to Equity Vistagen VTGN|OVID (Ovid Therapeutics Inc) - Long-Term Liabilities to Equity|Acumen Pharmaceuticals, Inc. - Long-Term Debt to Capital|Long-Term Liabilities to Capital CervoMed, Inc.|ATHE (alteritytherapeutics.com) - Long-Term Debt to Equity Ratio|Clene (CLNN) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio PEPG|JUNS (jupiterneurosciences.com) - Long-Term Loans to Capital Ratio|Long-Term Debt to Capital RLMD|Ratio of Long-Term Indebtedness to Capital Annovis Bio Inc|Long-Term Debt to Capital GRCE (Grace Therapeutics)|AIFF - Long-Term Debt to Equity Ratio|KLTO - Long-Term Debt to Equity|Ratio of Long-Term Indebtedness to Capital NeuroSense Therapeutics NRSN|RVPH: Long-Term Debt to Capital|MetaVia (MTVA) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio NRXS|HSDT (Helius Medical Technologies Inc.) - Long-Term Loans to Capital Ratio|Long-Term Debt to Equity Ratio PASG (Passage Bio, Inc.)|bionomics.com.au - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital NERV (Minerva Neurosciences, Inc.)|Ratio of Long-Term Indebtedness to Capital Athira Pharma Inc (ATHA)|ADXN - Long-Term Debt to Equity|ALZN (Alzamend Neuro, Inc.) - Long-Term Debt to Capital Ratio|CYCN: Long-Term Debt to Capital|Long-Term Liabilities to Capital Protagenic Therapeutics, Inc. (PTIX)|Long-Term Debt to Equity Ratio KTTA|Long-Term Debt to Capital Cortigent Medical|Long-Term Debt to Equity Brainstorm Cell Therapeutics, Inc. (BCLI)|CARA (Cara Therapeutics Inc) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Chromocell Therapeutics CHRO|Eliem Therapeutics, Inc. (ELYM) - Long-Term Liabilities to Capital|Intra-Cellular - Long-Term Debt to Capital|LBPH - Long-Term Debt to Capital|MRNS (Marinus) - Long-Term Debt to Equity Ratio|NKGN (NKGen Biotech Corp) - Long-Term Debt to Equity|NRBO (NeuroBo Pharmaceuticals) - Long-Term Debt to Capital|Long-Term Liabilities to Capital sagerx.com SAGE|Long-Term Debt to Equity Synaptogenix (SNPX)|Trevena Inc. - Long-Term Debt to Capital Ratio|Vigil Neuroscience, Inc. - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Anew Medical Inc. WENA|Cerevel Therapeutics - Long-Term Debt to Capital